

Benjamin Movsas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9607669/publications.pdf>

Version: 2024-02-01

52
papers

2,421
citations

346980

22
h-index

232693

48
g-index

53
all docs

53
docs citations

53
times ranked

4108
citing authors

#	ARTICLE	IF	CITATIONS
1	How Vital Are Patient-Reported Outcomes?. Journal of the National Cancer Institute, 2022, 114, 347-348.	3.0	9
2	Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2022, 112, 926-937.	0.4	11
3	Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium. International Journal of Radiation Oncology Biology Physics, 2022, 112, 942-950.	0.4	7
4	Radiomics outperforms clinical factors in characterizing human papilloma virus (HPV) for patients with oropharyngeal squamous cell carcinomas. Biomedical Physics and Engineering Express, 2022, 8, 045010.	0.6	5
5	Racial Differences in Treatments and Toxicity in Patients With Non-Small-Cell Lung Cancer Treated With Thoracic Radiation Therapy. JCO Oncology Practice, 2022, , OP2100224.	1.4	0
6	The Biological Process of Aging and the Impact of Ionizing Radiation. Seminars in Radiation Oncology, 2022, 32, 172-178.	1.0	8
7	Predictors of Toxicity Among Older Adults with Cancer. Seminars in Radiation Oncology, 2022, 32, 179-185.	1.0	0
8	American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020. Journal of Thoracic Oncology, 2021, 16, 66-75.	0.5	17
9	Therapeutic enhancement of radiation and immunomodulation by gold nanoparticles in triple negative breast cancer. Cancer Biology and Therapy, 2021, 22, 124-135.	1.5	28
10	Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Molecular Therapy - Oncolytics, 2021, 20, 94-104.	2.0	30
11	Technical note: On the development of an outcome-driven frequency filter for improving radiomics-based modeling of human papillomavirus (HPV) in patients with oropharyngeal squamous cell carcinoma. Medical Physics, 2021, 48, 7552-7562.	1.6	2
12	Cardiac Dose in Locally Advanced Lung Cancer: Results From a Statewide Consortium. Practical Radiation Oncology, 2020, 10, e27-e36.	1.1	12
13	Correlation of normal lung density changes with dose after stereotactic body radiotherapy (SBRT) for early stage lung cancer. Clinical and Translational Radiation Oncology, 2020, 22, 1-8.	0.9	8
14	CTNI-50. NEUROCOGNITIVE FUNCTION (NCF) OF THE PHOTON COHORT IN NRG-BN001. Neuro-Oncology, 2020, 22, ii53-ii54.	0.6	0
15	Automatic Segmentation of the Prostate on CT Images Using Deep Neural Networks (DNN). International Journal of Radiation Oncology Biology Physics, 2019, 104, 924-932.	0.4	66
16	Improvements in CBCT Image Quality Using a Novel Iterative Reconstruction Algorithm: A Clinical Evaluation. Advances in Radiation Oncology, 2019, 4, 390-400.	0.6	42
17	Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy. JAMA Oncology, 2019, 5, 664.	3.4	40
18	NCOG-01. NEUROCOGNITIVE FUNCTION (NCF) AND QUALITY OF LIFE (QOL) RESULTS FROM A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH RISK LOW-GRADE GLIOMAS. Neuro-Oncology, 2019, 21, vi158-vi159.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Clinical Outcome Assessments Toolbox for Radiopharmaceuticals. <i>Frontiers in Oncology</i> , 2019, 9, 1028.	1.3	1
20	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. <i>Neurosurgery</i> , 2019, 84, 66-76.	0.6	7
21	Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 30-45.	0.4	29
22	The value of collaboration between thoracic surgeons and radiation oncologists while awaiting evidence in operable stage I non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 429-431.	0.4	8
23	Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study. <i>Practical Radiation Oncology</i> , 2018, 8, 167-173.	1.1	19
24	Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities. <i>Advances in Radiation Oncology</i> , 2018, 3, 405-411.	0.6	3
25	On the impact of smoothing and noise on robustness of CT and CBCT radiomics features for patients with head and neck cancers. <i>Medical Physics</i> , 2017, 44, 1755-1770.	1.6	51
26	Radiation Therapy in Elderly Persons: An Old Issue With New Approaches. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 715-717.	0.4	4
27	Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. <i>Practical Radiation Oncology</i> , 2017, 7, 295-301.	1.1	339
28	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-small-Cell Lung Cancer (RTOG 3505). <i>Clinical Lung Cancer</i> , 2017, 18, 333-339.	1.1	47
29	Focusing on the "Person" in Personalized Medicine: The Future of Patient-Centered Care in Radiation Oncology. <i>Journal of the American College of Radiology</i> , 2016, 13, 1571-1578.	0.9	16
30	Quality of Life Analysis of a Radiation Dose Escalation Study of Patients With Non-small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 359.	3.4	145
31	In Reply to Mell. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 468-469.	0.4	0
32	Dosimetric evaluation of synthetic CT relative to bulk density assignment-based magnetic resonance-only approaches for prostate radiotherapy. <i>Radiation Oncology</i> , 2015, 10, 239.	1.2	46
33	Radiation dose-fractionation effects in spinal cord: comparison of animal and human data. <i>Journal of Radiation Oncology</i> , 2015, 4, 225-233.	0.7	6
34	Cultivating Tomorrow's Clinician Scientists: We Reap What We Sow. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 206-210.	0.4	17
35	Evaluating organ delineation, dose calculation and daily localization in an open-MRI simulation workflow for prostate cancer patients. <i>Radiation Oncology</i> , 2015, 10, 37.	1.2	26
36	PROceeding With the Patient-Reported Outcomes (PROs) Version of the Common Terminology Criteria for Adverse Events. <i>JAMA Oncology</i> , 2015, 1, 1059.	3.4	12

#	ARTICLE	IF	CITATIONS
37	Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 4106-4111.	0.8	265
38	Patient-Reported Outcomes and Survivorship in Radiation Oncology: Overcoming the Cons. <i>Journal of Clinical Oncology</i> , 2014, 32, 2920-2927.	0.8	43
39	Reply to M.J. Brenner et al and I.R. Vogelius et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1853-1854.	0.8	3
40	Recommended Patient-Reported Core Set of Symptoms to Measure in Head and Neck Cancer Treatment Trials. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	57
41	Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. <i>Practical Radiation Oncology</i> , 2014, 4, 187-191.	1.1	30
42	RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: Phase 2 results. <i>Practical Radiation Oncology</i> , 2014, 4, 76-81.	1.1	205
43	Impact of sociodemographic factors on the radiotherapeutic management of lung cancer: Results of a Quality Research in Radiation Oncology Survey. <i>Practical Radiation Oncology</i> , 2014, 4, e167-e179.	1.1	3
44	Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. <i>Practical Radiation Oncology</i> , 2011, 1, 60-71.	1.1	174
45	Decreasing the Adverse Effects of Cancer Therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators. <i>Clinical Cancer Research</i> , 2011, 17, 222-228.	3.2	34
46	Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 673-679.	0.5	16
47	Quality-of-life concerns in lung cancer patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 667-676.	0.7	8
48	Quality of Life Supersedes the Classic Prognosticators for Long-Term Survival in Locally Advanced Non-Small-Cell Lung Cancer: An Analysis of RTOG 9801. <i>Journal of Clinical Oncology</i> , 2009, 27, 5816-5822.	0.8	166
49	Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. <i>Journal of Neuro-Oncology</i> , 2009, 95, 247-257.	1.4	40
50	Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1341-1350.	1.5	18
51	Phase II Trial of Preoperative Chemoradiation With a Hyperfractionated Radiation Boost in Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 435-441.	0.6	19
52	Randomized Trial of Amifostine in Locally Advanced Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01. <i>Journal of Clinical Oncology</i> , 2005, 23, 2145-2154.	0.8	215